{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:14:07Z","timestamp":1778008447990,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"DOI":"10.7759\/cureus.108314","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:07:47Z","timestamp":1778008067000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimising Non-operative Management of Inoperable Malignant Bowel Obstruction: A Clinical Review for Surgical Practice"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Alkashty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab","family":"Kahka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Eshra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.02.028","article-title":"Management of malignant bowel obstruction","volume":"44","author":"Ripamonti CI","year":"2008","unstructured":"Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008, 44:1105-15. 10.1016\/j.ejca.2008.02.028","journal-title":"Eur J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S366680","article-title":"Inoperable bowel obstruction in ovarian cancer: prevalence, impact and management challenges","volume":"14","author":"Gonzalez-Ochoa E","year":"2022","unstructured":"Gonzalez-Ochoa E, Alqaisi HA, Bhat G, Jivraj N, Lheureux S. Inoperable bowel obstruction in ovarian cancer: prevalence, impact and management challenges. Int J Womens Health. 2022, 14:1849-62. 10.2147\/IJWH.S366680","journal-title":"Int J Womens Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020979773","article-title":"Medical management of inoperable malignant bowel obstruction","volume":"55","author":"Huang X","year":"2021","unstructured":"Huang X, Xue J, Gao M, Qin Q, Ma T, Li X, Wang H. Medical management of inoperable malignant bowel obstruction. Ann Pharmacother. 2021, 55:1134-45. 10.1177\/1060028020979773","journal-title":"Ann Pharmacother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.06.014","article-title":"Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review","volume":"33","author":"Mercadante S","year":"2007","unstructured":"Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage. 2007, 33:217-23. 10.1016\/j.jpainsymman.2006.06.014","journal-title":"J Pain Symptom Manage"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.12.006","article-title":"Octreotide for malignant bowel obstruction: twenty years after","volume":"83","author":"Mercadante S","year":"2012","unstructured":"Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol. 2012, 83:388-92. 10.1016\/j.critrevonc.2011.12.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-015-0455-3","article-title":"Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer","volume":"13","author":"Peng X","year":"2015","unstructured":"Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 2015, 13:50. 10.1186\/s12957-015-0455-3","journal-title":"World J Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00147-5","article-title":"Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction: a randomized trial","volume":"19","author":"Ripamonti C","year":"2000","unstructured":"Ripamonti C, Mercadante S, Groff L, et al.. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction: a randomized trial. J Pain Symptom Manage. 2000, 19:23-34. 10.1016\/S0885-3924(99)00147-5","journal-title":"J Pain Symptom Manage"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq048","article-title":"Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction","volume":"40","author":"Hisanaga T","year":"2010","unstructured":"Hisanaga T, Shinjo T, Morita T, et al.. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol. 2010, 40:739-45. 10.1093\/jjco\/hyq048","journal-title":"Jpn J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06438-9","article-title":"Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update","volume":"29","author":"Davis M","year":"2021","unstructured":"Davis M, Hui D, Davies A, et al.. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Support Care Cancer. 2021, 29:8089-96. 10.1007\/s00520-021-06438-9","journal-title":"Support Care Cancer"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1080\/J354v21n04_14","article-title":"Role of corticosteroids in palliative care","volume":"21","author":"Shih A","year":"2007","unstructured":"Shih A, Jackson KC 2nd. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother. 2007, 21:69-76.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001219","article-title":"Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer","volume":"2000","author":"Feuer DJ","year":"2000","unstructured":"Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000, 2000:CD001219. 10.1002\/14651858.CD001219","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/j.2055-2335.2011.tb00865.x","article-title":"Dexamethasone use in inpatient palliative care","volume":"41","author":"Kiani M","year":"2011","unstructured":"Kiani M, Yip AYM, Tuffin PHR, et al.. Dexamethasone use in inpatient palliative care. J Pharm Pract Res. 2011, 41:122-6. 10.1002\/j.2055-2335.2011.tb00865.x","journal-title":"J Pharm Pract Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.09.014","article-title":"Palliative management of inoperable malignant bowel obstruction: prospective, open label, Phase 2 study at an NCI Comprehensive Cancer Center","volume":"67","author":"Walter M","year":"2024","unstructured":"Walter M, Hansen E, Hamid S, et al.. Palliative management of inoperable malignant bowel obstruction: prospective, open label, Phase 2 study at an NCI Comprehensive Cancer Center. J Pain Symptom Manage. 2024, 67:20-6. 10.1016\/j.jpainsymman.2023.09.014","journal-title":"J Pain Symptom Manage"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s005200000198","article-title":"Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer","volume":"9","author":"Ripamonti C","year":"2001","unstructured":"Ripamonti C, Twycross R, Baines M, et al.. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001, 9:223-33. 10.1007\/s005200000198","journal-title":"Support Care Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2020.0101","article-title":"Olanzapine versus metoclopramide for nausea and vomiting in advanced cancer patients with incomplete bowel obstruction","volume":"23","author":"Kaneishi K","year":"2020","unstructured":"Kaneishi K, Imai K, Nishimura K, et al.. Olanzapine versus metoclopramide for nausea and vomiting in advanced cancer patients with incomplete bowel obstruction. J Palliat Med. 2020, 23:880-1. 10.1089\/jpm.2020.0101","journal-title":"J Palliat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/1049909115569047","article-title":"Medical therapy of malignant bowel obstruction with octreotide, dexamethasone, and metoclopramide","volume":"33","author":"Berger J","year":"2016","unstructured":"Berger J, Lester P, Rodrigues L. Medical therapy of malignant bowel obstruction with octreotide, dexamethasone, and metoclopramide. Am J Hosp Palliat Care. 2016, 33:407-10. 10.1177\/1049909115569047","journal-title":"Am J Hosp Palliat Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/1049909120968249","article-title":"Palliative medical management of inoperable malignant bowel obstruction with \u201ctriple therapy\u201d: dexamethasone, octreotide, and metoclopramide","volume":"38","author":"Wey W","year":"2021","unstructured":"Wey W, Mian M, Calabrese R, et al.. Palliative medical management of inoperable malignant bowel obstruction with \u201ctriple therapy\u201d: dexamethasone, octreotide, and metoclopramide. Am J Hosp Palliat Care. 2021, 38:340-5. 10.1177\/1049909120968249","journal-title":"Am J Hosp Palliat Care"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1177\/030089160509100304","article-title":"Management of symptoms due to inoperable bowel obstruction","volume":"91","author":"Ripamonti C","year":"2005","unstructured":"Ripamonti C, Fagnoni E, Magni A. Management of symptoms due to inoperable bowel obstruction. Tumori. 2005, 91:233-6.","journal-title":"Tumori"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.01.007","article-title":"Aggressive pharmacological treatment for reversing malignant bowel obstruction","volume":"28","author":"Mercadante S","year":"2004","unstructured":"Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage. 2004, 28:412-6. 10.1016\/j.jpainsymman.2004.01.007","journal-title":"J Pain Symptom Manage"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012014","article-title":"Oral water soluble contrast for malignant bowel obstruction","author":"Syrmis W","year":"2018","unstructured":"Syrmis W, Richard R, Jenkins-Marsh S, et al.. Oral water soluble contrast for malignant bowel obstruction. Cochrane Database Syst Rev. 2018, 10.1002\/14651858.CD012014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06889-8","article-title":"MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer","volume":"30","author":"Madariaga A","year":"2022","unstructured":"Madariaga A, Lau J, Ghoshal A, et al.. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer. Support Care Cancer. 2022, 30:4711-28. 10.1007\/s00520-022-06889-8","journal-title":"Support Care Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2482-13-S1-A27","article-title":"Colonic stenting in the management of malignant intestinal obstruction in elderly patients","volume":"13","author":"Maffioli A","year":"2013","unstructured":"Maffioli A, Bondurri A, Manes G, Cavallo D, Callioni S, Danelli PG. Colonic stenting in the management of malignant intestinal obstruction in elderly patients. BMC Surg. 2013, 13:A27. 10.1186\/1471-2482-13-S1-A27","journal-title":"BMC Surg"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07549-y","article-title":"Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide","volume":"20","author":"McCaffrey N","year":"2020","unstructured":"McCaffrey N, Asser T, Fazekas B, et al.. Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. BMC Cancer. 2020, 20:1050. 10.1186\/s12885-020-07549-y","journal-title":"BMC Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002164","article-title":"Survival, healthcare utilization, and end-of-life care among older adults with malignancy-associated bowel obstruction: comparative study of surgery, venting gastrostomy, or medical management","volume":"267","author":"Lilley EJ","year":"2018","unstructured":"Lilley EJ, Scott JW, Goldberg JE, et al.. Survival, healthcare utilization, and end-of-life care among older adults with malignancy-associated bowel obstruction: comparative study of surgery, venting gastrostomy, or medical management. Ann Surg. 2018, 267:692-9. 10.1097\/SLA.0000000000002164","journal-title":"Ann Surg"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00191-7","article-title":"Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial","volume":"8","author":"Krouse RS","year":"2023","unstructured":"Krouse RS, Anderson GL, Arnold KB, et al.. Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Lancet Gastroenterol Hepatol. 2023, 8:908-18. 10.1016\/S2468-1253(23)00191-7","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/489915-optimising-non-operative-management-of-inoperable-malignant-bowel-obstruction-a-clinical-review-for-surgical-practice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:07:49Z","timestamp":1778008069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/489915-optimising-non-operative-management-of-inoperable-malignant-bowel-obstruction-a-clinical-review-for-surgical-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.108314","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}